Well Referenced

Tag: progression-free survival

Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

This 2021 commentary by Hadaschik and Herrmann discusses the findings of the VISION trial, which evaluated the efficacy of Lutetium-177-PSMA-617 (Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC). The VISION trial demonstrated that Lu-PSMA-617, when added to standard care, significantly improved both imaging-based progression-free survival (8.7 vs. 3.4 months)

Read More »
June 26, 2025 No Comments

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

This retrospective study assessed the safety and efficacy of sirolimus, an mTOR inhibitor, combined with endocrine therapy in 36 patients with advanced hormone receptor-positive (HR+) breast cancer. The combination yielded a median progression-free survival (PFS) of 4.9 months and an objective response rate of 19.4%, with a clinical benefit rate

Read More »
June 26, 2025 No Comments

Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial

This 2021 phase 2 randomized clinical trial (MIRACLE study) assessed the benefit of adding everolimus to letrozole in premenopausal women with hormone receptor-positive, ERBB2-negative advanced breast cancer who had progressed on selective estrogen receptor modulators (SERMs). A total of 199 patients were randomized to receive either everolimus (10 mg/day) with

Read More »
June 26, 2025 No Comments

Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach

This 2019 study presents a novel statistical methodology to estimate tumor doubling times (TDTs) from published progression-free survival (PFS) plots, facilitating better understanding of tumor growth dynamics in solid malignancies. Researchers extracted PFS curves from clinical trials encompassing twelve cancer types, including pancreatic, melanoma, hepatocellular carcinoma, renal cell carcinoma, triple-negative

Read More »
June 26, 2025 No Comments

Hormone Maintenance Therapy for Women with Low-Grade Serous Ovarian Cancer in the Front-Line Setting: A Systematic Review

This 2021 systematic review evaluated the efficacy of hormone maintenance therapy (HMT) following cytoreductive surgery in women with low-grade serous ovarian cancer (LGSOC). Four cohort studies encompassing 558 patients (127 receiving HMT) were analyzed. The studies exhibited significant heterogeneity in HMT regimens, dosing, and patient populations. One retrospective study indicated

Read More »
June 26, 2025 No Comments

Improved Chemotherapy Outcomes of Patients With Small-cell Lung Cancer Treated With Combined Alkalization Therapy and Intravenous Vitamin C

This 2022 study evaluated the impact of combining alkalization therapy and intravenous vitamin C (IVC) with chemotherapy in patients with small-cell lung cancer (SCLC). The combination therapy aimed to neutralize the acidic tumor microenvironment and enhance the cytotoxic effects of chemotherapy. Results indicated that patients receiving the combined treatment exhibited

Read More »
June 26, 2025 No Comments

Association of statin use with clinical outcomes in patients with triple-negative breast cancer

This study investigates the impact of statin use on clinical outcomes in patients with triple-negative breast cancer (TNBC). The results suggest that statin use is associated with improved overall survival and progression-free survival in TNBC patients. The article explores the potential mechanisms, including statins’ effects on cholesterol metabolism and inflammation,

Read More »
June 26, 2025 No Comments

Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma

This retrospective cohort study assessed the impact of hormone replacement therapy (HRT) on survival outcomes in women under 50 treated for stage IB-IIB cervical adenocarcinoma. The study analyzed 58 patients divided into three groups: ovaries conserved (OVCON), iatrogenic menopause with HRT (IM-HRT), and iatrogenic menopause without HRT (IM-NOHRT). Five-year disease-specific

Read More »
June 26, 2025 No Comments